A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Stopped Sponsor's decision to terminate the development of the program due to changing landscape.
Conditions
Interventions
- DRUG: DSP-0509
- DRUG: DSP-0509, Pembrolizumab
- DRUG: DSP-0509, Pembrolizumab
Sponsor
Sumitomo Pharma America, Inc.
Collaborators